These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33581779)

  • 21. Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety.
    Zhao G; Huang T; Zheng M; Cui Y; Liu Y; Cheng Z; Wang Z
    Eur Neurol; 2018; 79(1-2):68-73. PubMed ID: 29241193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke in a local university hospital].
    Takahashi K; Iijima K; Oguro H; Bokura H; Nagai A; Yamaguchi S; Kobayashi S
    No To Shinkei; 2005 Aug; 57(8):683-8. PubMed ID: 16146212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry.
    Matsuo R; Kamouchi M; Ago T; Hata J; Shono Y; Kuroda J; Wakisaka Y; Sugimori H; Kitazono T;
    Geriatr Gerontol Int; 2014 Oct; 14(4):954-9. PubMed ID: 24320947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Favourable renal outcomes after intravenous thrombolytic therapy for acute ischemic stroke: Clinical implication of kidney-brain axis.
    Chang TH; Chiu PF; Tsai CC; Chang CH; Wu CL; Kor CT; Li JR; Kuo CL; Huang CS; Chu CC; Lin CM; Chang CC
    Nephrology (Carlton); 2019 Sep; 24(9):896-903. PubMed ID: 30334303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis.
    Dong Y; Han Y; Shen H; Wang Y; Ma F; Li H; Wang Y; Dong Q
    Stroke Vasc Neurol; 2020 Dec; 5(4):348-352. PubMed ID: 32611728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanical clot disruption following intravenous recombinant tissue plasminogen activator administration in non-responders.
    Kawakami T; Terakawa Y; Tsuruno T; Murata T; Nishio A; Ohata K
    Neurol Med Chir (Tokyo); 2010; 50(3):183-91. PubMed ID: 20339266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating Weight of Patients With Acute Stroke When Dosing for Thrombolysis.
    Barrow T; Khan MS; Halse O; Bentley P; Sharma P
    Stroke; 2016 Jan; 47(1):228-31. PubMed ID: 26556826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT).
    Mori E; Minematsu K; Nakagawara J; Yamaguchi T;
    J Stroke Cerebrovasc Dis; 2011 Nov; 20(6):517-22. PubMed ID: 20719535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of functional outcome in patients with stroke thrombolysis in a tertiary hospital in Malaysia.
    Tai MLS; Goh KJ; Kadir KAA; Zakaria MI; Yap JF; Tan KS
    Singapore Med J; 2019 May; 60(5):236-240. PubMed ID: 30488077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-β1 for treating ischemic stroke using tissue plasminogen activator.
    Qin Z; Chen L; Liu M; Tan H; Zheng L
    Neurol Sci; 2020 Jan; 41(1):139-147. PubMed ID: 31478148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.
    Alessi MC; Gaudin C; Grosjean P; Martin V; Timsit S; Mahagne MH; Larrue V; Sibon I; Zuber M; Brouns R; Montaner J; Castellanos M; Donazzolo Y; Cho TH; Suissa L; Mechtouff L; Derex L; Suchon P; Mezzapesa A; Nighoghossian N
    Cerebrovasc Dis; 2016; 42(5-6):404-414. PubMed ID: 27387478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Retrospective Study of thrombolysis with 0.6 mg/kg Recombinant Tissue Plasminogen Activator (rt-PA) in Mild Stroke.
    Yang J; Yu F; Liu H; An H; Xiong R; Huang D
    Sci Rep; 2016 Aug; 6():31344. PubMed ID: 27510959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multimode Computed-Tomography-Guided Thrombolysis under a Prolonged Time Window in Acute Ischemic Stroke Patients with Atrial Fibrillation.
    Yang Y; Sun W; Li D; Li XY; Wang XT; Li SC; Zhao HJ; Zhang JB
    Int Heart J; 2019 Jul; 60(4):822-829. PubMed ID: 31257338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study.
    Sørensen SB; Barazangi N; Chen C; Wong C; Grosvenor D; Rose J; Bedenk A; Morrow M; McDermott D; Hove JD; Tong DC
    J Stroke Cerebrovasc Dis; 2016 May; 25(5):1110-1118. PubMed ID: 26897101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
    Lorenzano S; Toni D;
    Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.
    Lawson TR; Brown IE; Westerkam DL; Blackhurst DW; Sternberg S; Leacock R; Nathaniel TI
    Restor Neurol Neurosci; 2015; 33(3):301-8. PubMed ID: 25698111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.